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Abstract
Cardiac morbidity, early mortality, and sudden death are the major consequences of
sickle cell disease (SCD) in patients surviving into adulthood. Pulmonary hypertension
(PH), elevated tricuspid regurgitant jet velocity (TRV), and diastolic dysfunction have
all been identified to correlate with early mortality in adults with SCD. However, the
unifying pathophysiology behind these abnormalities and its connection with early
mortality and sudden death have not been recognized previously. We have found that
SCD patients have a unique cardiomyopathy characterized by restrictive physiology
(diastolic dysfunction, left atrial dilation and normal systolic function) superimposed
on features of hyperdynamic circulation (left ventricular [LV] enlargement and eccentric
LV hypertrophy. The restrictive cardiomyopathy of SCD causes pulmonary congestion
and post-capillary PH. This can be detected by a mild elevation in TRV, which is likely
a marker of the SCD-related cardiomyopathy rather than pulmonary arterial disease.
Similar to other restrictive cardiomyopathies, the SCD cardiomyopathy predisposes to
arrhythmias  and sudden death,  even when pulmonary pressures  are  not  severely
elevated. We have also found that diffuse myocardial fibrosis is common in SCD and
may underlie the diastolic dysfunction, but more studies are needed to understand the
mechanisms of SCD-related cardiomyopathy and to identify new therapies to decrease
cardiac morbidity and improve the life expectancy of SCD patients.
Keywords: sickle cell, cardiomyopathy, restrictive physiology, pulmonary hyperten-
sion
1. Introduction
Improvements in the medical care of sickle cell disease (SCD) in the last few decades have led
to a significant decrease in childhood mortality in developed countries [1]. As more patients live
into adulthood, the cumulative burden of acute and chronic organ damage has become an
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important determinant of quality of life, morbidity, and life expectancy. Although definitive
data are lacking, the life expectancy of SCD patients does not appear to have improved in the
last 15 years, and adult SCD-related mortality may have increased [2, 3]. Cardiopulmonary
complications, including heart failure and arrhythmias, are the main causes of death in adults
with SCD [4]. Sudden unexplained death is reported in 25–30% of SCD patients, and these are
likely cardiopulmonary events [4, 5]. A number of studies conducted in the last two decades
have examined the cardiac pathology and cardiac mortality in SCD and have identified risk
factors for early mortality in SCD; however, a global understanding of the cardiac dysfunction
in SCD is still lacking. Of the known adverse cardiac risk factors, elevation of the tricuspid
regurgitant jet velocity (TRV) measured by echocardiography, pulmonary hypertension (PH),
and diastolic dysfunction are the most consistent predictors of early mortality in adults with
SCD [6–9]. The mechanisms and pathophysiology that link these risk factors to the cardiac
phenotype of SCD, and that underlie unexplained complications such as arrhythmias and
sudden death, are not clearly understood.
2. Pulmonary hypertension in SCD
PH has been recognized as a complication of SCD and a predictor of early mortality. Although
the causes of PH in SCD are not fully known, several factors have been suggested to play a
part in its pathogenesis, including endothelial dysfunction due to chronic hemolysis and
secondary nitric oxide depletion, hypoxia, and chronic thromboembolic disease [10–12].
Hemodynamically, PH can be pre-capillary or pulmonary arterial hypertension (PAH) or post-
capillary or pulmonary venous hypertension (PVH). PH is defined by a mean pulmonary
artery pressure (PAP) ≥ 25 mmHg as measured by right heart catheterization [13]. Patients with
PAH have a pulmonary capillary wedge pressure (PCWP) or left ventricular (LV) end-diastolic
pressure ≤ 15 mmHg, while patients with PVH have PCWP > 15 mmHg [13]. The echocardio-
graphic measurement of TRV, in combination with an estimated right atrial pressure, can be
used to estimate the systolic PAP.
Multiple studies have shown that the prevalence of elevated PAP as estimated by echocar-
diography using a TRV value ≥ 2.5 m/s is 20–30% in SCD [8, 14, 15]. In addition, elevated TRV
in SCD is associated with increased risk of early mortality in adults [8]. Although TRV
measurements correlate with PAP, the use of TRV as a sole criterion results in overdiagnosis
of PH [16]. Studies of right-sided heart catheterization, the gold standard to diagnose PH, have
shown that only about 30% of SCD patients with elevated TRV have PH [17, 18]. When PH is
present in SCD, PAP is usually only mildly elevated, and the pulmonary vascular resistance
is not increased compared to other patient populations with PH [7, 18, 19], and this does not
readily explain the associated risk of early mortality. Importantly, most SCD patients in these
studies with confirmed PH actually had PVH, which is caused by left-sided heart disease,
rather than PAH, which could be caused by endothelial dysfunction (Figure 1). In addition,
therapeutic trials of PAH-directed therapy in SCD were not successful and currently these
therapies are not recommended for treatment of PH in SCD [20, 21].
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Figure 1. The percentage of SCD patients with TRV ≥2.5 m/s who had confirmed PH (PAH or PVH) by right-sided
heart catheterization. Data are pooled from four different studies [7, 18, 22, 23].
These hemodynamic studies of SCD-related PH have improved our understanding of this
complication. PH is less prevalent in SCD than was suggested by echocardiographic screening
alone. It is also less severe and may be of a mixed origin, but most cases are caused by left-
sided heart disease as evidenced by the higher frequency of PVH rather than pulmonary
arterial disease. As a result, in 2013, The Fifth World Symposium on Pulmonary Hypertension
changed the classification of SCD-related PH from “Group 1,” which indicates pulmonary
arterial hypertension to “Group 5,” which refers to pulmonary hypertension with unclear or
multifactorial mechanisms [13, 24]. Despite the poor diagnostic accuracy of TRV for PH, TRV
is still a predictor of early mortality in adults with SCD; however, the exact cause of elevated
TRV in the absence of PH and the mechanisms by which it confers increased mortality risk are
poorly understood. However, elevated TRV is not associated with early mortality in children.
3. Diastolic dysfunction in SCD
Recently, diastolic dysfunction has also been recognized as an independent risk factor for
mortality in SCD [9]. Diastolic dysfunction is common in SCD and was found in nearly all
studies that evaluated diastolic function [17]. The prevalence and severity of diastolic dys-
function vary across studies, ranging from 11 to 77% depending on the criteria used to define
diastolic dysfunction in each study. This wide range also reflects the challenges of diagnosing
diastolic dysfunction and the lack of agreement on diagnostic criteria and classification of
diastolic dysfunction in SCD. Nonetheless, common echocardiographic estimates of diastolic
function are clearly abnormal in SCD. The ratio of early to late mitral flow velocities (E/A ratio),
tissue Doppler annular velocities (e.g.; E/e’ and e’/a’ ratios), and left atrial (LA) volumes are
significantly abnormal in SCD, and some of these measures correlate with early mortality in
SCD [9, 14, 25, 26]. Diastolic dysfunction can be detected early in life in SCD patients, and even
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children may have severe diastolic dysfunction [25, 27–29]. This suggests that diastolic
dysfunction likely precedes other non–anemia-related hemodynamic changes in SCD [17].
Diastolic dysfunction ranges in severity from an impaired relaxation of the ventricles to
irreversible restrictive ventricular filling [30]. Progressive worsening of diastolic function
eventually causes an increase in LV filling pressures and LA pressures. The elevated LA
pressure, which correlates with chronic LA enlargement and an elevation in the diastolic
estimate E/e’ ratio, leads to an increase in PCWP and some degree of PH [31]. Diastolic
dysfunction is the major cause of PVH in SCD [32]. Despite the significance of diastolic
dysfunction in SCD, there is still a need to define diastolic dysfunction and identify diastolic
function parameters that are least affected by the hyperdynamic state of SCD. There is also a
lack of understanding of the mechanisms that predispose to diastolic dysfunction in SCD.
Cardiac iron overload, which plays a major part in cardiac pathology and diastolic dysfunction
in thalassemia [33], is rare in SCD [34, 35] and unlikely to be a major cause of diastolic
dysfunction in most individuals. More studies are needed to identify the underlying cause of
diastolic dysfunction in SCD [36].
4. Anemia-related hyperdynamic features
The complex effects of chronic anemia on the heart are the result of various compensatory
cardiovascular mechanisms to anemia. Altered blood viscosity, tissue hypoxia, and increased
sympathetic tone are some of the factors that drive cardiovascular hemodynamic changes in
anemia [37]. Chronic anemia causes arteriolar dilation and decreased afterload, while the
decreased venous tone increases the preload. The increased preload, coupled with increased
sympathetic tone, leads to increased stroke volume and cardiac output. Together, these
changes lead to a state of volume overload [38–40]. Chronic volume overload and increased
cardiac load over time leads to cardiac enlargement and left ventricular hypertrophy (LVH)
[41]. LVH is an adaptive mechanism to prolonged volume or pressure overload. In states of
volume overload, LVH is eccentric and defined by increased LV internal dimension with a
normal ratio of wall thickness to cavity diameter (a proportionate increase in wall thickness
and LV internal diameter). In contrast, concentric hypertrophy, which results from pressure
overload (e.g., aortic stenosis), is characterized by increased wall thickness without a change
in the ventricular chamber radius [42]. Unlike the adaptive eccentric hypertrophy of volume
overload, concentric hypertrophy can become maladaptive and may lead to ventricular
stiffening and heart failure over time. Typical features of volume overload characterize the
hearts of SCD patients: increased stroke volume and cardiac output, increased LV end-diastolic
dimensions, and eccentric LVH [17]. It is also important to note that LV dilation in SCD is
associated with an increased ejection fraction and stroke volume and is different from LV
dilation of “failing” ventricles, typically seen in dilated cardiomyopathies, where LV dilation
is associated with LV systolic dysfunction. While anemia-related hyperdynamic features are
prominent in SCD, it is difficult to differentiate fully the effects of anemia from the effects of
other pathologic processes of SCD, such as vaso-occlusion and inflammation, in the heart. The
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contribution of anemic-hyperdynamic features to other pathologic cardiac features (i.e.,
diastolic dysfunction, elevated TRV, and PH) has yet to be established.
5. The cardiomyopathy of SCD
Until recently, there has not been a unifying cardiac pathophysiology identified to explain the
cardiac features of SCD: mild PH, elevated TRV, diastolic dysfunction, LA dilation, and LV
dilation with normal systolic function. We have reported that patients with SCD have a unique
cardiomyopathy with restrictive physiology that is superimposed on hyperdynamic features
[17]. This cardiomyopathy with restrictive physiology provides an explanation for most
cardiac features of SCD.
5.1. Restrictive cardiac physiology
Restrictive physiology is essentially defined by a stiff myocardium that causes the ventricular
pressure to rise precipitously with only small increases in volume [43]. It is primarily a disease
of the heart muscle that causes decreased myocardial compliance and, therefore, diastolic
dysfunction, resulting in elevation in ventricular filling pressures and LA pressures and
restricted filling. Restrictive cardiomyopathies (RCM) can be primary, which constitutes 5% of
primary cardiomyopathies [44], or secondary to infiltrative diseases (e.g., sarcoidosis or
amyloidosis), radiation, or chemotherapy [45]. Progressive fibrosis of the myocardium leading
to impaired ventricular relaxation and progressive diastolic dysfunction is the primary
mechanism underlying the different forms of RCM. RCM is defined by diastolic dysfunction,
atrial enlargement, normal systolic function, and ventricles of normal size [44]. Unlike systolic
cardiomyopathies, e.g., dilated cardiomyopathy, which is characterized by enlarged ventricles
with decreased systolic function, RCM is a primary diastolic cardiomyopathy and the ven-
tricular volumes are normal or small in primary RCM. The outcome of primary RCM is poor
without heart transplantation. Age and LA size are the strongest predictors of mortality in
RCM [46]. PH, venous and arterial, is a well-known consequence of RCM that is associated
with a worse outcome [47]. In addition, ischemia and arrhythmias, likely from fibrosis encasing
the conducting pathways, are the most common causes of death in RCM [48]. Indeed, sudden
unexpected death happens in about 30% of patients with RCM [44].
5.2. Cardiomyopathy with restrictive physiology in SCD
We reviewed the echocardiographic data on SCD patients at Cincinnati Children’s Hospital
Medical Center and conducted a meta-analysis of reported cardiac studies in SCD. Across all
the studies, we observed a pattern consistent with a cardiomyopathy with combined features
of restrictive physiology and hyperdynamic circulation. The primary features of the SCD-
related cardiomyopathy are (1) diastolic dysfunction, (2) LA dilation, and (3) LV enlargement
with normal systolic function [17]. One main difference between primary RCM and the
restrictive cardiomyopathy of SCD is LV enlargement, which is not seen in primary RCM.
Indeed, formal criteria for RCM exclude enlarged ventricles, but this distinction is made to
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differentiate RCM from dilated cardiomyopathy. While small- or normal-size ventricles define
primary RCM, which distinguishes it from the dilated cardiomyopathies with systolic
dysfunction, the LV enlargement in SCD is associated with normal or even increased systolic
function in SCD. Therefore, LV dilation is one of the hyperdynamic features that coexists with
the features of restrictive physiology in the hearts of SCD patients.
Figure 2. The percentage of SCD patients with low E/A ratio and septal e’ (z-score less than −1) in the following age
groups: 1–5 years, 6–9 years, 10–17 years, and older than 18 years.
In our echocardiographic study of 134 patients with SCD (age range from 3 to 22 years),
diastolic dysfunction and LA enlargement were common [17]. Impaired relaxation, as reflected
by abnormal tissue Doppler early velocity e’ and decreased E/A ratio, worsened with age
(Figure 2), while severe diastolic dysfunction, defined by severely abnormal E/e’ ratio, was
seen in up to 14% of this group of young patients. In addition, LA enlargement was observed
in 62% of patients and was the most enlarged heart chamber. While LV enlargement and
eccentric LVH were also observed, LA enlargement was more common and disproportionate
to LV enlargement, reflecting the different mechanisms underlying LV and LA enlargement.
Similar to other studies in SCD, the systolic function was normal in our study [49].
The same cardiac pattern was observed in a meta-analysis of the published cardiac studies in
SCD, combining data on more than 5000 patients from 68 different studies [17]. LV enlargement
was more pronounced in the meta-analysis as it included older patients with more severe
anemia. Consistent with previous studies, we confirmed that LA enlargement is an early
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cardiac feature that precedes the enlargement of other cardiac chambers in SCD [27, 50–52].
Over time, LV enlargement and LVH become more prominent because of chronic volume
overload [41, 49]. At that later stage, the SCD cardiomyopathy can be described by 4-chamber
enlargement, diastolic dysfunction, and normal systolic function [36]. However, the restrictive
physiology remains an important and an early hemodynamic feature of the SCD cardiomy-
opathy that can be masked by the 4-chamber enlargement in adults with SCD. Increased LV
filling and LA pressures characterize restrictive physiology, which subsequently leads to mild
PVH and TRV elevation. Indeed, TRV was significantly associated with the restrictive com-
ponent of the SCD cardiomyopathy (diastolic dysfunction and LA enlargement), suggesting
that TRV is likely a marker of the restrictive cardiomyopathy of SCD [17].
Figure 3. Schema of the proposed pathophysiologic construct of the cardiomyopathy of SCD.
In summary, the SCD-related cardiomyopathy is a restrictive cardiomyopathy, defined by
diastolic dysfunction and LA enlargement, superimposed on hyperdynamic features of LV
enlargement with normal systolic function. The SCD cardiomyopathy causes passive pulmo-
nary congestion and mild PVH, which is common in SCD, and causes mild elevation in TRV
that is detected by echocardiography (Figure 3). Interestingly, both PVH and PAH can result
from diastolic failure and restrictive physiology [32]. This unique cardiomyopathy seen in most
patients with SCD may coincide with PAH (confirmed by right heart catheterization with low
PCWP and elevated pulmonary vascular resistance), possibly caused by endothelial dysfunc-
tion, in a small group of patients. However, the majority of SCD patients with cardiac dys-
function lack hemodynamic evidence of PAH, and most of their cardiac pathology can be
explained by this unique SCD-related cardiomyopathy. The similarities in the patterns and
frequency of mortality between SCD patients and patients with primary RCM are notable. The
The Cardiomyopathy of Sickle Cell Disease
http://dx.doi.org/10.5772/64321
101
high rate of arrhythmias and sudden death, especially at times of stress, are common conse-
quences of restrictive physiology in RCM and are complications of SCD that have not been
explained and can likely be attributed to the restrictive cardiomyopathy of SCD.
5.3. Myocardial tissue characterization in SCD: cardiac MRI and autopsy studies
The cause of diastolic dysfunction and restrictive physiology in SCD is unclear. Cardiac MRI
(CMR) studies have shown that cardiac iron overload is rare in SCD patients, even when
systemic iron overload is present [36, 53, 54], and is unlikely to be a primary mechanism
underlying cardiac dysfunction in SCD. The small number of autopsy studies in SCD provided
the earliest insight into cardiac histopathology in SCD. Some of the findings in autopsy
specimens include chamber enlargement and increased heart weight, pulmonary vascular
changes [55, 56], and myocardial fibrosis [36, 56, 57]. Different myocardial fibrosis patterns
were noted: transmural fibrosis/scarring without evidence of atherosclerosis, patchy fibrosis,
diffuse myocardial fibrosis, and fibrotic foci involving the conduction system predisposing to
arrhythmias [36, 58].
Recent CMR studies have provided further information about the tissue characteristics of the
sickle hearts using non-invasive techniques. One technique, late gadolinium enhancement
(LGE), is useful in detecting scar tissue or focal macroscopic fibrosis based on differences in
the volumes of distribution of the extracellular contrast agent, gadolinium [59]. In SCD, LGE
detection has been variable. Most CMR studies detected LGE in a subset of patients, reaching
up to 25% of evaluated patients in one study [36, 54, 60–63]. However, because this technique
is based on detecting differences in enhancement between the affected area and surrounding
myocardial tissue, it will not detect diffuse myocardial fibrosis, which was also seen in the
autopsies of SCD patients [36]. These autopsy and CMR studies suggest that fibrosis is
probably an overlooked pathology that contributes to cardiac dysfunction in SCD. Studies are
ongoing using novel CMR techniques to better characterize myocardial tissue and assess
myocardial fibrosis non-invasively in SCD. Indeed, early findings from our ongoing CMR
study indicate that diffuse myocardial fibrosis is common in SCD [64]. This and future studies
may shed some light on the pathogenic mechanisms that underlie the cardiomyopathy of SCD.
6. Screening, diagnosis, and treatment of cardiac dysfunction in SCD
Based on the high prevalence of abnormal TRV and its correlation with PH, echocardiographic
screening for PH in SCD was adopted by some groups [8]. However, because of the low
predictive value of TRV in diagnosing PH in SCD and the lack of interventions that have been
shown to change the outcome, if PH is detected early, echocardiographic screening for PH in
SCD has become controversial. The 2014 National Heart, Lung and Blood Institute (NHLBI)
Expert Panel’s report on evidence-based management of SCD patients did not find sufficient
evidence to make a recommendation for echocardiographic screening of asymptomatic SCD
patients [65]. On the other hand, The American Thoracic Society Clinical Practice Guidelines
suggested performing echocardiography every 1–3 year and increasing the frequency of
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screening depending on the presence of adverse risk factors (high TRV and elevated serum
NT-pro-BNP or confirmed PH) [21]. However, these are experts’ opinions that are not sup-
ported by strong evidence at this point. Despite incomplete information about its different
causes, an elevated TRV is an adverse prognostic marker in adults with SCD, irrespective of
PH, and this finding should prompt increased clinical vigilance. Although it is not clear when
to begin screening and how often to continue it, at our pediatric institution, we perform a
screening echocardiogram and electrocardiogram on asymptomatic individuals with SCD
starting between the ages of 15 and 18 years. We screen for chamber enlargement, especially
of the LA, systolic function, and diastolic abnormalities using mitral inflow and tissue Doppler
annular velocities, and elevated TRV. If cardiac abnormalities are identified, the need for
follow-up imaging and referral to a cardiologist is determined individually.
Similar to the difficulties in diagnosis and screening strategies, there is no proven treatment
for cardiac dysfunction or PH in SCD. Few, small observational studies showed a potential
effect of PAH-directed therapy in SCD-related PH [66–68], but randomized controlled trials
did not demonstrate any benefit for these therapies in SCD. Small randomized controlled trials
using the endothelin receptor antagonist bosentan in SCD patients with PH were terminated
early due to slow enrollment [20], and a trial comparing sildenafil to placebo in SCD patients
with elevated TRV was also terminated early because of adverse events [69]. Experts’ guide-
lines recommend against the use of PAH-directed therapy in SCD [21, 65]. The role of disease-
modifying therapies (i.e., hydroxyurea and transfusions) in the treatment of PH or SCD-related
cardiomyopathy is also undetermined. Limited available data suggest that hydroxyurea may
be beneficial in improving TRV elevation in young patients with SCD [70, 71]. However,
transfusion therapy has not been studied in PH or cardiomyopathy. The American Thoracic
Society expert’s panel recommends using hydroxyurea for patients with increased mortality
risk or chronic transfusions for patients who cannot take or were unresponsive to hydroxyurea.
However, these recommendations are based on the overall beneficial effects of these disease-
modifying therapies in ameliorating other aspects of SCD and not based on a demonstrated
cardiopulmonary benefit [21]. Understanding the mechanisms underlying the SCD-related
cardiomyopathy and different forms of PH in SCD will be important to identify directed
therapies to slow or reverse cardiac dysfunction in SCD. Until then, optimizing general SCD
care (e.g., beginning or optimizing hydroxyurea or chronic transfusion therapy) is the only
therapeutic option with established benefits for SCD patients.
7. Conclusions
The SCD-related cardiomyopathy is a unique restrictive cardiomyopathy superimposed on LV
enlargement and LVH due to hyperdynamic circulation. SCD-related cardiomyopathy is
characterized by diastolic dysfunction, LA enlargement, and normal systolic function with LV
enlargement. This restrictive cardiomyopathy leads to mild PH and mild elevation in TRV.
Similar to other restrictive cardiomyopathies, the SCD-related cardiomyopathy may predis-
pose to arrhythmias and sudden death. Diffuse myocardial fibrosis may be an underlying
mechanism of the restrictive cardiac physiology of SCD. Definitively establishing the mecha-
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nisms underlying diastolic dysfunction and the SCD-related cardiomyopathy may lead to
specific, targeted therapy to slow or reverse the cardiomyopathy and decrease the morbidity
and early mortality of SCD.
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